Yeruham, Israel – 3R Pharma Ltd, a preclinical-stage pharmaceutical company-up focused on developing novel cannabinoid-based therapies for ophthalmic diseases, today announced that Prof. Avi Solomon had joined the company’s Scientific Advisory Board (SAB). In this role, Prof. Solomon will provide strategic guidance and clinical expertise to the company’s research and development programs.

Prof. Solomon is a Cornea and Refractive Surgery specialist with extensive experience in managing dry eye syndrome, blepharitis, corneal infections, keratoconus, pterygium, and challenging cases of severe chemical and thermal burns of the ocular surface, and severe inflammatory diseases of the cornea and conjunctiva. He is an Associate Professor in the Ophthalmology Department at the Hadassah – Hebrew University Medical Center in Jerusalem and has published numerous papers in leading peer-reviewed journals in Ophthalmology. Prof. Solomon’s clinical interests include Cornea and External Eye Diseases, with particular emphasis on ocular surface disorders and ocular surface.

“We are thrilled to welcome Prof. Avi Solomon to our Scientific Advisory Board,” said Michael Rubinov, CEO of 3R Pharma. “His medical expertise and clinical research in the area of ocular surface diseases will be invaluable as we continue to advance our pipeline of cannabinoids based innovative therapies for serious ophthalmic conditions that are not sufficiently addressed today. Prof. Solomon’s insight and guidance will help us make important strategic decisions and move our programs forward with greater speed and efficiency.”

“I am excited to join the 3R Pharma Scientific Advisory Board and contribute to developing new therapies for patients who suffer from Dry Eye disease,” said Prof. Avi Solomon. “3R Pharma’s commitment to innovation and its focus on unmet medical needs make it an ideal partner for my research interests. I look forward to working with the team to advance these promising programs.”

About 3R Pharma LTD.

3R Pharma is a preclinical pharmaceutical technology company focused on developing cannabinoids based innovative therapies for ophthalmic ocular surface diseases. The company’s pipeline includes several product candidates in various stages of development, including preclinical and clinical trials. 3R Pharma is committed to bringing life-changing treatments to patients in need and improving their quality of life.

Media Contact:

Eden Chen
www.3Rpharma.com
+972-544-742750
eden@3Rpharma.com